Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Alkermes (ALKS) today and set a price target of $45. The company’s shares opened today at $32.90, close to its 52-week low of $27.54.
According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 3.0% and a 43.7% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as G1 Therapeutics Inc, Puma Biotechnology, and Seres Therapeutics.
The word on The Street in general, suggests a Hold analyst consensus rating for Alkermes with a $40.22 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $71.22 and a one-year low of $27.54. Currently, Alkermes has an average volume of 894.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alkermes Plc IS a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. It operates through the following geographical segments: U.S., Ireland, Rest of the World, and Other.
